RxSight, Inc. (NASDAQ:RXST) Stock Holdings Decreased by Pure Financial Advisors LLC

Pure Financial Advisors LLC lessened its position in RxSight, Inc. (NASDAQ:RXST) by 21.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,412 shares of the company’s stock after selling 3,980 shares during the quarter. Pure Financial Advisors LLC’s holdings in RxSight were worth $867,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CWM LLC boosted its position in shares of RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares during the period. Larson Financial Group LLC purchased a new position in RxSight during the 1st quarter valued at about $51,000. RiverPark Advisors LLC increased its holdings in shares of RxSight by 361.4% in the 1st quarter. RiverPark Advisors LLC now owns 3,082 shares of the company’s stock valued at $159,000 after purchasing an additional 2,414 shares during the period. Amalgamated Bank lifted its position in shares of RxSight by 7.7% in the fourth quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock worth $167,000 after purchasing an additional 298 shares in the last quarter. Finally, Clear Rock Advisors LLC purchased a new stake in shares of RxSight in the fourth quarter worth approximately $172,000. Institutional investors and hedge funds own 78.78% of the company’s stock.

Insider Transactions at RxSight

In other RxSight news, insider Ilya Goldshleger sold 9,000 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $39.25, for a total transaction of $353,250.00. Following the completion of the sale, the insider now directly owns 42,246 shares in the company, valued at $1,658,155.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Julie Andrews sold 15,625 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $58.00, for a total transaction of $906,250.00. Following the transaction, the director now owns 30,287 shares of the company’s stock, valued at $1,756,646. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ilya Goldshleger sold 9,000 shares of the company’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.25, for a total transaction of $353,250.00. Following the transaction, the insider now owns 42,246 shares of the company’s stock, valued at $1,658,155.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,625 shares of company stock worth $1,845,600. 9.36% of the stock is owned by insiders.

RxSight Stock Up 4.0 %

Shares of NASDAQ:RXST traded up $2.05 on Friday, reaching $52.79. The company had a trading volume of 513,079 shares, compared to its average volume of 495,392. The stock has a market capitalization of $1.95 billion, a P/E ratio of -41.90 and a beta of 1.19. The stock has a 50-day moving average price of $51.92 and a 200 day moving average price of $53.54. RxSight, Inc. has a twelve month low of $20.66 and a twelve month high of $66.54.

RxSight (NASDAQ:RXST) last posted its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The firm had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. During the same period in the previous year, the company earned ($0.40) EPS. The company’s revenue for the quarter was up 67.6% on a year-over-year basis. On average, sell-side analysts predict that RxSight, Inc. will post -0.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on RXST shares. BTIG Research upped their price objective on shares of RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Oppenheimer dropped their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus lowered their target price on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Wells Fargo & Company dropped their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Finally, Needham & Company LLC reduced their price target on RxSight from $75.00 to $54.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $58.43.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.